The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward
Open accessAbstract
Sanofi Pasteur has developed a recombinant, live-attenuated, tetravalent dengue vaccine (CYD-TDV) that is in late-stage development. The present review summarizes the different steps in the development of this dengue vaccine, with a particular focus on the clinical data from three efficacy trials, which includes one proof-of-concept phase IIb (NCT00842530) and two pivotal phase III efficacy trials (NCT01373281 and NCT01374516). Earlier studies showed that the CYD-TDV candidate had a satisfactory safety profile and was immunogenic across the four vaccine serotypes in both in vitro and in vivo preclinical tests, as well as in initial phase I to phase II clinical trials in both flavivirus-naïve and seropositive individuals. Data from the 25 months (after the first injection) active phase of the two pivotal phase III efficacy studies shows that CYD-TDV (administered at 0, 6, and 12 months) is efficacious against virologically-confirmed disease (primary endpoint) and has a good safety profile. Secondary analyses also showed efficacy against all four dengue serotypes and protection against severe disease and hospitalization. The end of the active phases in these studies completes more than a decade of development of CYD-TDV, but considerable activities and efforts remain to address outstanding scientific, clinical, and immunological questions, while preparing for the introduction and use of CYD-TDV. Additional safety observations were recently reported from the first complete year of hospital phase longer term surveillance for two phase 3 studies and the first and second completed years for one phase 2b study, demonstrating the optimal age for intervention from 9 years. Dengue is a complex disease, and both short-term and long-term safety and efficacy will continue to be addressed by ongoing long-term follow-up and future post-licensure studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global distribution and burden of dengue
Bhatt, S., Gething, P. W., Brady, O. J., Messina, J. P., Farlow, A. W., Moyes, C. L., Drake, J. M., Brownstein, J. S., Hoen, A. G., Sankoh, O., et al. (2013) · Nature · doi:10.1038/nature12060 · Cited by 10,037
Dengue: a continuing global threat
Guzman, M. G., Halstead, S. B., Artsob, H., Buchy, P., Farrar, J., Gubler, D. J., Hunsperger, E., Kroeger, A., Margolis, H. S., Martínez, E., et al. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2460 · Cited by 2,082
Cited by
Guzman, M. G., Gubler, D. J., Izquierdo, A., Martinez, E., & Halstead, S. B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.55 · Cited by 762
Dengue virus: epidemiology, biology, and disease aetiology
Roy, S. K., & Bhattacharjee, S. (2021) · Canadian Journal of Microbiology · doi:10.1139/cjm-2020-0572 · Cited by 440
A review of Dengvaxia®: development to deployment
Thomas, S. J., & Yoon, I.-K. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1658503 · Cited by 331
Metadata
- Authors
- Guy, B., Briand, O., Lang, J., Saville, M., & Jackson, N.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 33
- Issue
- 50
- Pages
- 7100-7111
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2106800284
- Cited by
- 172
- References
- 2
- FWCI
- 24.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward. https://app.cochat.ai/papers/10.1016/j.vaccine.2015.09.108
- The paper
- Guy, B., Briand, O., Lang, J., Saville, M., & Jackson, N. (2015). Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward. Vaccine. https://doi.org/10.1016/j.vaccine.2015.09.108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.